These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 32116253

  • 1. Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years.
    Kapoor A, Bartha R, Black SE, Borrie M, Freedman M, Gao F, Herrmann N, Mandzia J, Ozzoude M, Ramirez J, Scott CJM, Symons S, Fischer CE, Frank A, Seitz D, Wolf MU, Verhoeff NPLG, Naglie G, Reichman W, Masellis M, Mitchell SB, Tang-Wai DF, Tartaglia MC, Kumar S, Pollock BG, Rajji TK, Finger E, Pasternak SH, ONDRI Investigators, Swartz RH.
    J Alzheimers Dis; 2020; 74(3):747-757. PubMed ID: 32116253
    [Abstract] [Full Text] [Related]

  • 2. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y, Ito K, Arima K, Matsuda H, Nakata Y, Sakata M, Sato N, Nakagome K, Motohashi N.
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [Abstract] [Full Text] [Related]

  • 3. A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.
    Spasov S, Passamonti L, Duggento A, Liò P, Toschi N, Alzheimer's Disease Neuroimaging Initiative.
    Neuroimage; 2019 Apr 01; 189():276-287. PubMed ID: 30654174
    [Abstract] [Full Text] [Related]

  • 4. Role of inflammatory and hemostatic biomarkers in Alzheimer's and vascular dementia - A pilot study from a tertiary center in Northern India.
    Vishnu VY, Modi M, Garg VK, Mohanty M, Goyal MK, Lal V, Mittal BR, Prabhakar S.
    Asian J Psychiatr; 2017 Oct 01; 29():59-62. PubMed ID: 29061429
    [Abstract] [Full Text] [Related]

  • 5. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M, National Institute on Aging (u.s.), Alzheimer Association.
    Rev Neurol (Paris); 2012 Jun 01; 168(6-7):471-82. PubMed ID: 22579080
    [Abstract] [Full Text] [Related]

  • 6. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
    Tiepolt S, Patt M, Hoffmann KT, Schroeter ML, Sabri O, Barthel H.
    J Alzheimers Dis; 2015 Jun 01; 47(3):539-43. PubMed ID: 26401690
    [Abstract] [Full Text] [Related]

  • 7. Imaging discrepancies between magnetic resonance imaging and brain perfusion single-photon emission computed tomography in the diagnosis of Alzheimer's disease, and verification with amyloid positron emission tomography.
    Yokoyama S, Kajiya Y, Yoshinaga T, Tani A, Hirano H.
    Psychogeriatrics; 2014 Jun 01; 14(2):110-7. PubMed ID: 24954834
    [Abstract] [Full Text] [Related]

  • 8. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T, Arighi A, Sacchi L, Fumagalli GG, Pietroboni AM, Ghezzi L, Colombi A, Scarioni M, Fenoglio C, De Riz MA, Marotta G, Scarpini E, Galimberti D.
    Alzheimers Res Ther; 2019 Oct 15; 11(1):84. PubMed ID: 31615545
    [Abstract] [Full Text] [Related]

  • 9. The Whole Picture: From Isolated to Global MRI Measures of Neurovascular and Neurodegenerative Disease.
    Dickie DA, Quinn TJ, Dawson J.
    Adv Exp Med Biol; 2019 Oct 15; 1205():25-53. PubMed ID: 31894568
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
    Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, Ohlsson T, Jögi J, Palmqvist S, Mattsson-Carlgren N, Strandberg O, Stomrud E, Hansson O.
    JAMA Neurol; 2020 Aug 01; 77(8):955-965. PubMed ID: 32391858
    [Abstract] [Full Text] [Related]

  • 11. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M, Noda Y, Shinagawa S, Chung JK, Sawada K, Ogyu K, Tarumi R, Tsugawa S, Miyazaki T, Yamagata B, Graff-Guerrero A, Mimura M, Nakajima S, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2018 Aug 01; 63(2):861-869. PubMed ID: 29689728
    [Abstract] [Full Text] [Related]

  • 12. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
    Kitajima K, Abe K, Takeda M, Yoshikawa H, Ohigashi M, Osugi K, Koyama H, Yamakado K.
    Medicine (Baltimore); 2021 Jan 22; 100(3):e23969. PubMed ID: 33545981
    [Abstract] [Full Text] [Related]

  • 13. Differential diagnosis of mild cognitive impairment and Alzheimer's disease using structural MRI cortical thickness, hippocampal shape, hippocampal texture, and volumetry.
    Sørensen L, Igel C, Pai A, Balas I, Anker C, Lillholm M, Nielsen M, Alzheimer’s Disease Neuroimaging Initiative and the Australian Imaging Biomarkers and Lifestyle flagship study of ageing.
    Neuroimage Clin; 2017 Jan 22; 13():470-482. PubMed ID: 28119818
    [Abstract] [Full Text] [Related]

  • 14. Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment.
    Chandra A, Dervenoulas G, Politis M, Alzheimer’s Disease Neuroimaging Initiative.
    J Neurol; 2019 Jun 22; 266(6):1293-1302. PubMed ID: 30120563
    [Abstract] [Full Text] [Related]

  • 15. Potential Role of Neuroimaging Markers for Early Diagnosis of Dementia in Primary Care.
    Teipel S, Kilimann I, Thyrian JR, Kloppel S, Hoffmann W.
    Curr Alzheimer Res; 2018 Jun 22; 15(1):18-27. PubMed ID: 28891447
    [Abstract] [Full Text] [Related]

  • 16. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L, Lobsien D, Fritzsch D, Tiepolt S, Werner P, Schroeter ML, Berrouschot J, Saur D, Hesse S, Jochimsen T, Rullmann M, Sattler B, Patt M, Gertz HJ, Villringer A, Claßen J, Hoffmann KT, Sabri O, Barthel H.
    Eur J Nucl Med Mol Imaging; 2016 Nov 22; 43(12):2236-2243. PubMed ID: 27435367
    [Abstract] [Full Text] [Related]

  • 17. Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content.
    Bouhrara M, Reiter DA, Bergeron CM, Zukley LM, Ferrucci L, Resnick SM, Spencer RG.
    Alzheimers Dement; 2018 Aug 22; 14(8):998-1004. PubMed ID: 29679574
    [Abstract] [Full Text] [Related]

  • 18. Predicting progression from mild cognitive impairment to Alzheimer's disease on an individual subject basis by applying the CARE index across different independent cohorts.
    Chen J, Chen G, Shu H, Chen G, Ward BD, Wang Z, Liu D, Antuono PG, Li SJ, Zhang Z, Alzheimer’s Disease Neuroimaging InitiativeA complete listing of ADNI investigators can be found at at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf..
    Aging (Albany NY); 2019 Apr 30; 11(8):2185-2201. PubMed ID: 31078129
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P, Dean RA, Hall SD, Qi Y, Sethuraman G, Willis BA, Siemers ER, Martenyi F, Tauscher JT, Schwarz AJ.
    J Alzheimers Dis; 2012 Apr 30; 32(2):373-85. PubMed ID: 22796873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.